| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Thomas Wessel last filed a Form 4 in January 2018, as Chief Medical Officer at DCOY. Thomas Wessel's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 57,064 shares of DCOY. Net of sales, the DCOY filings show accumulation of 20,000 shares.
Thomas Wessel has 4 Form 4 filings on record from January 2016 to January 2018, all as Chief Medical Officer at Salarius Pharmaceuticals (DCOY), 2016–2018.
The 5 reported transactions were 3 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $159K and no sales.
The only open-market purchase was 20,000 shares of DCOY at an average $7.94 on March 14, 2016, about $159K.
Shares as reported in the last Form 4 for each company; the most recent is from January 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2016 | DCOY Salarius Pharmaceuticals, Inc. | Chief Medical Officer | Buy | 20,000 | $7.94 | $158,840.00 | +54.0% |